Real-world Effectiveness and Tolerability of Interferon-free Direct-acting Antiviral for 15,849 Patients with Chronic Hepatitis C: A Multinational Cohort Study

Fanpu Ji¹, Sally Tran², Eiichi Ogawa³, Chung-Feng Huang^{4

5}, Takanori Suzuki⁶, Yu Jun Wong^{7

8}, Hidenori Toyoda⁹, Dae Won Jun^{10

11}, Liu Li¹², Haruki Uojima¹³, Akito Nozaki¹⁴, Makoto Chuma¹⁴, Cheng-Hao Tseng¹⁵, Yao-Chun Hsu¹⁵, Masatoshi Ishigami¹⁶, Takashi Honda¹⁶, Masanori Atsukawa¹⁷, Hiroaki Haga¹⁸, Masaru Enomoto¹⁹, Huy Trinh²⁰, Carmen Monica Preda²¹, Phillip Vutien²², Charles Landis²², Dong Hyun Lee²³, Tsunamasa Watanabe²⁴, Hirokazu Takahashi^{25

26}, Hiroshi Abe²⁷, Akira Asai²⁸, Yuichiro Eguchi^{25

29}, Jie Li³⁰, Xiaozhong Wang³¹, Jia Li³², Junping Liu³³, Jing Liang³⁴, Carla Pui-Mei Lam³⁵, Rui Huang³⁰, Qing Ye³⁴, Hongying Pan³⁶, Jiajie Zhang³⁶, Dachuan Cai³⁷, Qi Wang³⁸, Daniel Q Huang^{39

40}, Grace Wong^{41

42}, Vincent Wai-Sun Wong⁴¹, Junyi Li¹², Son Do⁴³, Norihiro Furusyo⁴⁴, Makoto Nakamuta⁴⁵, Hideyuki Nomura⁴⁶, Eiji Kajiwara⁴⁷, Eileen L Yoon^{10

11}, Sang Bong Ahn⁴⁸, Koichi Azuma⁴⁹, Kazufumi Dohmen⁵⁰, Jihyun An⁵¹, Do Seon Song⁵², Hyun Chin Cho⁵³, Akira Kawano⁵⁴, Toshimasa Koyanagi⁵⁵, Aritsune Ooho⁵⁶, Takeaki Satoh⁵⁷, Kazuhiro Takahashi⁵⁸, Ming-Lun Yeh^{4

5}, Pei-Chien Tsai^{4

5}, Satoshi Yasuda⁹, Yunyu Zhao¹, Yishan Liu¹, Tomomi Okubo⁵⁹, Norio Itokawa¹⁷, Mi Jung Jun²³, Toru Ishikawa⁶⁰, Koichi Takaguchi⁶¹, Tomonori Senoh⁶¹, Mingyuan Zhang⁶², Changqing Zhao⁶³, Raluca Ioana Alecu²¹, Wei Xuan Tay⁷, Pooja Devan⁷, Joanne Kimiko Liu²², Ritsuzo Kozuka⁶⁴, Elena Vargas-Accarino⁶⁵, Ai-Thien Do⁴³, Mayumi Maeda², Wan-Long Chuang⁴, Jee-Fu Huang^{4

5}, Chia-Yen Dai^{4

5}, Ramsey Cheung^{2

66}, Maria Buti^{65

67}, Junqi Niu⁶², Wen Xie³⁸, Hong Ren³⁷, Seng Gee Lim^{39

40}, Chao Wu³⁰, Man-Fung Yuen^{35

68}, Jia Shang³³, Qiang Zhu⁶⁹, Yoshiyuki Ueno¹⁸, Yasuhito Tanaka^{6

70}, Jun Hayashi⁷¹, Ming-Lung Yu^{4

5

72}, Mindie H Nguyen^{2

73}

Affiliations

¹ Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
² Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Palo Alto, CA, USA.
³ Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan.
⁴ Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung.
⁵ Hepatitis Research Center, College of Medicine and Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung.
⁶ Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
⁷ Gastroenterology & Hepatology, Changi General Hospital, Singhealth, Singapore.
⁸ Singhealth Duke-NUS Medicine Academic Clinical Program, Singapore.
⁹ Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan.
¹⁰ Department of Internal Medicine, Hanyang University, College of Medicine, Seoul, Korea.
¹¹ Hanyang Institute of Bioscience and Biotechnology, Hanyang University, Seoul, Korea.
¹² Department of Hepatology, The Third People's Hospital of Kunming City, Kunming, Yunnan, China.
¹³ Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
¹⁴ Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan.
¹⁵ Division of Gastroenterology and Hepatology, Department of Internal Medicine, E-Da Cancer Hospital, Kaohsiung.
¹⁶ Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
¹⁷ Division of Gastroenterology and Hepatology, Nippon Medical School, Tokyo, Japan.
¹⁸ Department of Gastroenterology, Yamagata University Faculty of Medicine, Yamagata, Japan.
¹⁹ Department of Transfusion Medicine and Department of Hepatology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
²⁰ San Jose Gastroenterology, San Jose, CA, USA.
²¹ Gastroenterology & Hepatology Department, Clinic Fundeni Institute, Bucharest, Romania.
²² Division of Gastroenterology and Hepatology, University of Washington, Seattle, WA, USA.
²³ Department of Gastroenterology, Good Gang-An Hospital, Busan, Korea.
²⁴ Division of Gastroenterology and Hepatology, St. Marianna University School of Medicine, Kawasaki, Japan.
²⁵ Liver Center, Saga University Hospital, Saga, Japan.
²⁶ Division of Metabolism and Endocrinology, Saga University Faculty of Medicine, Saga, Japan.
²⁷ Division of Gastroenterology and Hepatology, Shinmatsudo Central General Hospital, Chiba, Japan.
²⁸ 2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
²⁹ Locomedical General Institute, Locomedical Eguchi Hospital, Saga, Japan.
³⁰ Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
³¹ Affiliated Traditional Chinese Medicine Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
³² Department of Gastroenterology and Hepatology, The Second People's Hospital of Tianjin, Tianjin, China.
³³ Department of Infectious Diseases, Henan Provincial People's Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan, China.
³⁴ Department of Gastroenterology and Hepatology, The Third Central Hospital of Tianjin, Tianjin, China.
³⁵ Department of Medicine, The University of Hong Kong, Hong Kong, China.
³⁶ Department of Hepatology, Zhejiang Provincial People's Hospital Affiliated to Zhejiang University, Hangzhou, Zhejiang, China.
³⁷ Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
³⁸ Center of liver diseases, Beijing Ditan Hospital Affiliated to Capital Medical University, Beijing, China.
³⁹ Division of Gastroenterology and Hepatology, National University Hospital, Singapore.
⁴⁰ Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
⁴¹ Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
⁴² State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China.
⁴³ Digestive Health Associates of Texas, Dallas, TX, USA.
⁴⁴ Taihaku Avenue Clinic, Fukuoka, Japan.
⁴⁵ Department of Gastroenterology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
⁴⁶ Department of Internal Medicine, Haradoi Hospital, Fukuoka, Japan.
⁴⁷ Hepatology Clinic, Kajiwara Clinic, Kitakyushu, Japan.
⁴⁸ Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University College of Medicine, Seoul, Korea.
⁴⁹ Department of Medicine, Kyushu Central Hospital, Fukuoka, Japan.
⁵⁰ Department of Internal Medicine, Chihaya Hospital, Fukuoka, Japan.
⁵¹ Department of Internal Medicine, Hanyang University, College of Medicine, Guri Hospital, Guri, Korea.
⁵² Division of Hepatology, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.
⁵³ Departments of Internal Medicine, Gyeongsang National University Hospital, Jinju, Korea.
⁵⁴ Department of Medicine, Kitakyushu Municipal Medical Center, Fukuoka, Japan.
⁵⁵ Department of Medicine, Fukuoka City Hospital, Fukuoka, Japan.
⁵⁶ Department of Hepatology, Steel Memorial Yawata Hospital, Kitakyushu, Japan.
⁵⁷ Center for Liver Disease, National Hospital Organization Kokura Medical Center, Kitakyushu, Japan.
⁵⁸ Department of Medicine, Hamanomachi Hospital, Fukuoka, Japan.
⁵⁹ Division of Gastoroentelorogy, Nippon Medcal School Chiba Hokusoh Hospital, Chiba, Japan.
⁶⁰ Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
⁶¹ Department of Hepatology, Kagawa Prefectural Central Hospital, Kagawa, Japan.
⁶² Department of Hepatology, The First Hospital of Jilin University, Changchun, Jilin, China.
⁶³ Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
⁶⁴ Department of Hepatology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
⁶⁵ Liver Diseases Group, Vall d'Hebron Research Institute, Barcelona, Spain.
⁶⁶ Division of Gastroenterology and Hepatology, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
⁶⁷ Liver Unit, Department of Internal Medicine, Hospital Universitari Valle d'Hebron and Universitat Autònoma de Barcelona, Barcelona, Spain.
⁶⁸ State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China.
⁶⁹ Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University, Ji'nan, Shandong, China.
⁷⁰ Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
⁷¹ Kyushu General Internal Medicine Center, Haradoi Hospital, Fukuoka, Japan.
⁷² School of Medicine and Doctoral Program of Clinical and Experimental Medicine, College of Medicine and Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University, Kaohsiung.
⁷³ Department of Epidemiology and Population Health, Stanford University, Stanford, CA, USA.

PMID: 38993510
PMCID: PMC11233980
DOI: 10.14218/JCTH.2024.00089

Real-world Effectiveness and Tolerability of Interferon-free Direct-acting Antiviral for 15,849 Patients with Chronic Hepatitis C: A Multinational Cohort Study

Fanpu Ji et al. J Clin Transl Hepatol. 2024.

. 2024 Jul 28;12(7):646-658.

doi: 10.14218/JCTH.2024.00089. Epub 2024 Jun 17.

Authors

Affiliations

¹ Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
² Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University Medical Center, Palo Alto, CA, USA.
³ Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan.
⁴ Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung.
⁵ Hepatitis Research Center, College of Medicine and Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung.
⁶ Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
⁷ Gastroenterology & Hepatology, Changi General Hospital, Singhealth, Singapore.
⁸ Singhealth Duke-NUS Medicine Academic Clinical Program, Singapore.
⁹ Department of Gastroenterology, Ogaki Municipal Hospital, Ogaki, Japan.
¹⁰ Department of Internal Medicine, Hanyang University, College of Medicine, Seoul, Korea.
¹¹ Hanyang Institute of Bioscience and Biotechnology, Hanyang University, Seoul, Korea.
¹² Department of Hepatology, The Third People's Hospital of Kunming City, Kunming, Yunnan, China.
¹³ Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
¹⁴ Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan.
¹⁵ Division of Gastroenterology and Hepatology, Department of Internal Medicine, E-Da Cancer Hospital, Kaohsiung.
¹⁶ Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
¹⁷ Division of Gastroenterology and Hepatology, Nippon Medical School, Tokyo, Japan.
¹⁸ Department of Gastroenterology, Yamagata University Faculty of Medicine, Yamagata, Japan.
¹⁹ Department of Transfusion Medicine and Department of Hepatology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
²⁰ San Jose Gastroenterology, San Jose, CA, USA.
²¹ Gastroenterology & Hepatology Department, Clinic Fundeni Institute, Bucharest, Romania.
²² Division of Gastroenterology and Hepatology, University of Washington, Seattle, WA, USA.
²³ Department of Gastroenterology, Good Gang-An Hospital, Busan, Korea.
²⁴ Division of Gastroenterology and Hepatology, St. Marianna University School of Medicine, Kawasaki, Japan.
²⁵ Liver Center, Saga University Hospital, Saga, Japan.
²⁶ Division of Metabolism and Endocrinology, Saga University Faculty of Medicine, Saga, Japan.
²⁷ Division of Gastroenterology and Hepatology, Shinmatsudo Central General Hospital, Chiba, Japan.
²⁸ 2nd Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
²⁹ Locomedical General Institute, Locomedical Eguchi Hospital, Saga, Japan.
³⁰ Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
³¹ Affiliated Traditional Chinese Medicine Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
³² Department of Gastroenterology and Hepatology, The Second People's Hospital of Tianjin, Tianjin, China.
³³ Department of Infectious Diseases, Henan Provincial People's Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan, China.
³⁴ Department of Gastroenterology and Hepatology, The Third Central Hospital of Tianjin, Tianjin, China.
³⁵ Department of Medicine, The University of Hong Kong, Hong Kong, China.
³⁶ Department of Hepatology, Zhejiang Provincial People's Hospital Affiliated to Zhejiang University, Hangzhou, Zhejiang, China.
³⁷ Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
³⁸ Center of liver diseases, Beijing Ditan Hospital Affiliated to Capital Medical University, Beijing, China.
³⁹ Division of Gastroenterology and Hepatology, National University Hospital, Singapore.
⁴⁰ Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
⁴¹ Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
⁴² State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China.
⁴³ Digestive Health Associates of Texas, Dallas, TX, USA.
⁴⁴ Taihaku Avenue Clinic, Fukuoka, Japan.
⁴⁵ Department of Gastroenterology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
⁴⁶ Department of Internal Medicine, Haradoi Hospital, Fukuoka, Japan.
⁴⁷ Hepatology Clinic, Kajiwara Clinic, Kitakyushu, Japan.
⁴⁸ Department of Internal Medicine, Nowon Eulji Medical Center, Eulji University College of Medicine, Seoul, Korea.
⁴⁹ Department of Medicine, Kyushu Central Hospital, Fukuoka, Japan.
⁵⁰ Department of Internal Medicine, Chihaya Hospital, Fukuoka, Japan.
⁵¹ Department of Internal Medicine, Hanyang University, College of Medicine, Guri Hospital, Guri, Korea.
⁵² Division of Hepatology, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.
⁵³ Departments of Internal Medicine, Gyeongsang National University Hospital, Jinju, Korea.
⁵⁴ Department of Medicine, Kitakyushu Municipal Medical Center, Fukuoka, Japan.
⁵⁵ Department of Medicine, Fukuoka City Hospital, Fukuoka, Japan.
⁵⁶ Department of Hepatology, Steel Memorial Yawata Hospital, Kitakyushu, Japan.
⁵⁷ Center for Liver Disease, National Hospital Organization Kokura Medical Center, Kitakyushu, Japan.
⁵⁸ Department of Medicine, Hamanomachi Hospital, Fukuoka, Japan.
⁵⁹ Division of Gastoroentelorogy, Nippon Medcal School Chiba Hokusoh Hospital, Chiba, Japan.
⁶⁰ Department of Gastroenterology, Saiseikai Niigata Hospital, Niigata, Japan.
⁶¹ Department of Hepatology, Kagawa Prefectural Central Hospital, Kagawa, Japan.
⁶² Department of Hepatology, The First Hospital of Jilin University, Changchun, Jilin, China.
⁶³ Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
⁶⁴ Department of Hepatology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
⁶⁵ Liver Diseases Group, Vall d'Hebron Research Institute, Barcelona, Spain.
⁶⁶ Division of Gastroenterology and Hepatology, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
⁶⁷ Liver Unit, Department of Internal Medicine, Hospital Universitari Valle d'Hebron and Universitat Autònoma de Barcelona, Barcelona, Spain.
⁶⁸ State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China.
⁶⁹ Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University, Ji'nan, Shandong, China.
⁷⁰ Department of Gastroenterology and Hepatology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
⁷¹ Kyushu General Internal Medicine Center, Haradoi Hospital, Fukuoka, Japan.
⁷² School of Medicine and Doctoral Program of Clinical and Experimental Medicine, College of Medicine and Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University, Kaohsiung.
⁷³ Department of Epidemiology and Population Health, Stanford University, Stanford, CA, USA.

PMID: 38993510
PMCID: PMC11233980
DOI: 10.14218/JCTH.2024.00089

Abstract

Background and aims: As practice patterns and hepatitis C virus (HCV) genotypes (GT) vary geographically, a global real-world study from both East and West covering all GTs can help inform practice policy toward the 2030 HCV elimination goal. This study aimed to assess the effectiveness and tolerability of DAA treatment in routine clinical practice in a multinational cohort for patients infected with all HCV GTs, focusing on GT3 and GT6.

Methods: We analyzed the sustained virological response (SVR12) of 15,849 chronic hepatitis C patients from 39 Real-World Evidence from the Asia Liver Consortium for HCV clinical sites in Asia Pacific, North America, and Europe between 07/01/2014-07/01/2021.

Results: The mean age was 62±13 years, with 49.6% male. The demographic breakdown was 91.1% Asian (52.9% Japanese, 25.7% Chinese/Taiwanese, 5.4% Korean, 3.3% Malaysian, and 2.9% Vietnamese), 6.4% White, 1.3% Hispanic/Latino, and 1% Black/African-American. Additionally, 34.8% had cirrhosis, 8.6% had hepatocellular carcinoma (HCC), and 24.9% were treatment-experienced (20.7% with interferon, 4.3% with direct-acting antivirals). The largest group was GT1 (10,246 [64.6%]), followed by GT2 (3,686 [23.2%]), GT3 (1,151 [7.2%]), GT6 (457 [2.8%]), GT4 (47 [0.3%]), GT5 (1 [0.006%]), and untyped GTs (261 [1.6%]). The overall SVR12 was 96.9%, with rates over 95% for GT1/2/3/6 but 91.5% for GT4. SVR12 for GT3 was 95.1% overall, 98.2% for GT3a, and 94.0% for GT3b. SVR12 was 98.3% overall for GT6, lower for patients with cirrhosis and treatment-experienced (TE) (93.8%) but ≥97.5% for treatment-naive patients regardless of cirrhosis status. On multivariable analysis, advanced age, prior treatment failure, cirrhosis, active HCC, and GT3/4 were independent predictors of lower SVR12, while being Asian was a significant predictor of achieving SVR12.

Conclusions: In this diverse multinational real-world cohort of patients with various GTs, the overall cure rate was 96.9%, despite large numbers of patients with cirrhosis, HCC, TE, and GT3/6. SVR12 for GT3/6 with cirrhosis and TE was lower but still excellent (>91%).

Keywords: DAA; Genotype; Hepatitis C virus; Hepatocellular carcinoma; Liver cirrhosis; REAL-C.

PubMed Disclaimer

Conflict of interest statement

FJ: Speaker fees: Gilead Sciences, MSD, and Ascletis. Consultancy: Gilead Sciences, MSD. FJ has been an Editorial Board Member of Journal of Clinical and Translational Hepatology since 2023. YJW: Speaker fees: Gilead Science, AbbVie. Research Grant: Medicine Academic Clinical Program, SingHealth, Singapore. YJW has been an Editorial Board Member of Journal of Clinical and Translational Hepatology since 2020. HT: Speaker fees: Gilead Science, AbbVie, Eisai, Fujifilm WAKO, Takeda, Kowa, Terumo, Astra Zeneca. VWSW: Consultancy: AbbVie, Boehringer Ingelheim, Echosens, Gilead Sciences, Intercept, Inventiva, Novo Nordisk, Pfizer, Sagimet Biosciences, TARGET PharmaSolutions, Visirna. Speaker fees: Abbott, AbbVie, Gilead Sciences, Novo Nordisk, Unilab. Research grants: Gilead Sciences. Stock: Co-founder of Illuminatio Medical Technology Limited. MA: Speakers’ fees: AbbVie, Gilead Sciences. SD: Speakers fees: Gilead Sciences. MFY: Speakers’ fees: Fujirebio Incorporation, Gilead Sciences, Roche, Sysmex Corporation. Consulting or advisory board: AbbVie, Abbott Diagnostics, Aligos Therapeutics, AiCuris, Antios Therapeutics, Arbutus Biopharma, Arrowhead Pharmaceuticals, Assembly Biosciences, Clear B Therapeutics, Dicerna Pharmaceuticals, Finch Therapeutics, Fujirebio Incorporation, GlaxoSmithKline, Gilead Sciences, Immunocore, Janssen, Precision BioSciences, Roche, Sysmex Corporation, Tune Therapeutics, Vir Biotechnology and Visirna Therapeutics. Research grant: AbbVie, Assembly Biosciences, Arrowhead Pharmaceuticals, Fujirebio Incorporation, Gilead Sciences, Immunocore, Sysmex Corporation and Roche. MFY has been an Associate Editor of Journal of Clinical and Translational Hepatology since 2021. CW: Research grant: Gilead Sciences. MLYu: Research support (grant) from Abbvie, BMS, Gilead, Merck, and Roche diagnostics. Consultant of Abbvie, BMS, Gilead, Roche, and Roche diagnostics. Speaker of Abbvie, BMS, Eisai, Gilead, Roche, and Roche diagnostics. MLYu has been an Associate Editor of Journal of Clinical and Translational Hepatology since 2023. MHN: Research grants via institution: Pfizer, Enanta, Astra Zeneca, GSK, Delfi, Innogen, Exact Science, CurveBio, Gilead, Vir Biotech, Helio Health, National Cancer Institute, Glycotest. Consulting/Advisory board: Intercept, Exact Science, Gilead, GSK. JL, MLYe, WLC and JFH have been Editorial Board Members of Journal of Clinical and Translational Hepatology since 2022. HR has been an Editor-in-Chief of Journal of Clinical and Translational Hepatology since 2013. The other authors have no conflict of interests related to this publication.

Figures

**Fig. 1. Sustained virologic response at week 12 after end-of-treatment (SVR12) rates for patients with chronic hepatitis C.**
Renal dysfunction was defined as an estimated glomerular filtration rate (eGFR) less than 60 (mL/m/1.73 m²). HCC, Hepatocellular carcinoma; CH, Chronic hepatitis; LC, Liver cirrhosis; GT, Genotype; SOF, Sofosbuvir; VEL, Velpatasvir; RBV, Ribavirin; DCV, Daclatasvir; ASV, Asunaprevir; LDV, Ledipasvir; PrOD, Paritaprevir/ritonavir, ombitasvir + dasabuvir; EBR, Elbasvir; GZR, Grazoprevir; GLE, Glecaprevir; PIB, Pibrentasvir; CI, Confidence interval.

Fig. 2. Sustained virologic response at week 12 after end-of-treatment (SVR12) rates for patients with chronic hepatitis C virus stratified by genotypes (GTs), liver fibrosis stage, and prior treatment.
CH, Chronic hepatitis; LC, Liver cirrhosis; TE, Treatment-experienced; TN, Treatment-naive; CI, Confidence interval.

See this image and copyright information in PMC

References

1. Thrift AP, El-Serag HB, Kanwal F. Global epidemiology and burden of HCV infection and HCV-related disease. Nat Rev Gastroenterol Hepatol. 2017;14(2):122–132. doi: 10.1038/nrgastro.2016.176. - DOI - PubMed
1. Polaris Observatory HCV Collaborators Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022;7(5):396–415. doi: 10.1016/S2468-1253(21)00472-6. - DOI - PubMed
1. Ogawa E, Chien N, Kam L, Yeo YH, Ji F, Huang DQ, et al. Association of Direct-Acting Antiviral Therapy With Liver and Nonliver Complications and Long-term Mortality in Patients With Chronic Hepatitis C. JAMA Intern Med. 2023;183(2):97–105. doi: 10.1001/jamainternmed.2022.5699. - DOI - PMC - PubMed
1. Calvaruso V, Craxì A. Hepatic benefits of HCV cure. J Hepatol. 2020;73(6):1548–1556. doi: 10.1016/j.jhep.2020.08.006. - DOI - PubMed
1. McCombs J, Matsuda T, Tonnu-Mihara I, Saab S, Hines P, L’italien G, et al. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. JAMA Intern Med. 2014;174(2):204–212. doi: 10.1001/jamainternmed.2013.12505. - DOI - PubMed

LinkOut - more resources

Full Text Sources
- PubMed Central
- Xia & He Publishing Inc.
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Real-world Effectiveness and Tolerability of Interferon-free Direct-acting Antiviral for 15,849 Patients with Chronic Hepatitis C: A Multinational Cohort Study

Affiliations

Real-world Effectiveness and Tolerability of Interferon-free Direct-acting Antiviral for 15,849 Patients with Chronic Hepatitis C: A Multinational Cohort Study

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

References

LinkOut - more resources

Full Text Sources

Research Materials

Miscellaneous